Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > New partnership provides affordable insulin for all in the USA
The cost of a vial of insulin has tripled in the USA over the last ten years, with prices currently ranging from between $175 (£130) and $300 (£224) per vial, which could cost a person up to $1,000 (£750) a month.
An estimated one in four people who are insulin dependent say they skip or ration their insulin because they cannot afford to pay this inflated price, potentially leading to severe consequences for their health, medical emergencies, or even death.
This groundbreaking partnership between JDRF International – who are based in the USA – and other funders, means that Civica, a nonprofit generic drug manufacturing company, can manufacture and distribute biosimilar insulin for no more than $30 (£23) a vial, or $55 (£40) for a box of five pen cartridges. This is as much as 90% lower than existing costs.
To make this happen, JDRF International has agreed to underwrite the initial development costs, meaning that Civica is able to provide this low-cost option to people who need it.
Civica will develop biosimilars to three of the most commonly used insulins in the USA, to reach the most people possible: glargine (Lantus®), lispro (Humalog®), and aspart (Novolog®). Biosimilar insulin is highly similar to existing insulins that are already licensed for use and are just as effective.
These affordable insulins will be available from 2024 to allow time for development, clinical trials and FDA approval, amongst other logistical factors. Everyone – regardless of their health insurance status – will be able to access this affordable insulin at this cost. This distinguishes this programme from many other existing routes of access for affordable insulin.
JDRF UK’s Chief Executive, Karen Addington, said: “We are today proud of the impact that JDRF achieves: this partnership will help resolve some of the systemic health inequality for people living with type 1 diabetes in the USA.
“It is our hope that this initiative then has the potential to go on and save lives across the world. We know that this news today will resonate with so many of our supporters and stakeholders who live with type 1 or work to prevent, treat and cure type 1 diabetes.”
Read JDRFI’s press release.
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
Genetically engineered beta cells transplanted into mice with type 1 diabetes avoid immune system attack and stabilise blood glucose levels without immunosuppressants.
We’re excited to reveal the first research projects funded by the Type 1 Diabetes Grand Challenge, our partnership with the Steve Morgan Foundation and Diabetes UK.